New antiretroviral strategies: interview with Marcus Conant, M.D. Interview by John S. James.
Conant
M
M
D000998:Antiviral Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count / Q000187:drug effects; D004279:DNA, Viral / Q000032:analysis; D004359:Drug Therapy, Combination; D006678:HIV / Q000235:genetics; D015658:HIV Infections / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D007546:Isoquinolines / Q000627:therapeutic use; D019259:Lamivudine; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced; D011480:Protease Inhibitors / Q000627:therapeutic use; D011804:Quinolines / Q000627:therapeutic use; D019258:Saquinavir; D018119:Stavudine / Q000008:administration & dosage; D016047:Zalcitabine / Q000008:administration & dosage / Q000031:analogs & derivatives; D015215:Zidovudine / Q000008:administration & dosage
D000998:Antiviral Agents; D004279:DNA, Viral; D007546:Isoquinolines; D011480:Protease Inhibitors; D011804:Quinolines; D019259:Lamivudine; D015215:Zidovudine; D016047:Zalcitabine; D018119:Stavudine; D019258:Saquinavir